Registry of Acute Myocardial Infarction

Status Recruiting

Clinical Trial Summary

The Registry of Acute Myocardial Infarction (RAMI) aims at regular and centralized acquiring and processing standard information about verified and suspected cases of acute myocardial infarction (AMI), monitoring of AMI cases, and establishing AMI diagnosis based on standard diagnostic criteria by doctors involved in the registry. The RAMI obtains data from all medical institutions, which could potentially document any cases of suspected AMI.

Clinical Trial Description

The study implements the methodology recommended by the World Health Organization (WHO) using unified diagnostic criteria (clinical, biochemical, electrocardiographic, and autopsy) for acute myocardial infarction (AMI). All primary information is recorded in a special primary registration card, which has been subject to updates in accordance with the requirements. All accumulated data is stored in RAMI analytic database. The database is designed and developed specifically for recording, accumulating, archiving, and statistical processing of collected data. It is equipped with a web user interface, a universal environment for generating consolidated distribution reporting, and the ability to import analytical data into expert analytical systems produced by other manufacturers. Data storage is implemented using the Oracle database management system. The information and analytical system of RAMI has passed the procedure of state registration of the database. Each reported case after the first 28 days from disease onset is assigned a specific diagnostic category (definite myocardial infarction, possible myocardial infarction, unconfirmed myocardial infarction, and insufficient data). At the end of each year of study, RAMI team calculates and analyzes the main epidemiological parameters, characterizing the disease distribution in the studied population (the city of Tomsk, Russian Federation) including morbidity, mortality, and lethality (general, in-hospital, and pre-hospital). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06252168
Study type	Observational
Source	Tomsk National Research Medical Center of the Russian Academy of Sciences
Contact	Sergey A. Okrugin, MD, PhD
Phone	+73822554111
Email	sao@cardio-tomsk.ru
Status	Recruiting
Phase
Start date	January 1, 1984
Completion date	December 31, 2050

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05759078` - Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion	Phase 4
Recruiting	`NCT06038994` - Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
Recruiting	`NCT04968808` - Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)	N/A
Completed	`NCT03338504` - Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Recruiting	`NCT03317691` - The ALERT-Pilot Study	N/A
Active, not recruiting	`NCT05077683` - Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF	Phase 3
Recruiting	`NCT03957005` - Cardiovascular Risk Assessment Model in Patients With MI
Enrolling by invitation	`NCT05955950` - Gratitude Intervention in Promoting Self-care in Patients With Myocardial Infarction	N/A
Active, not recruiting	`NCT06141252` - Benefit of Hypothermia in OHCA Complicating AMI	N/A
Not yet recruiting	`NCT04560023` - Effectiveness of Multimedia Exposure in Patients Transferred to Hospital Suffering From Acute Myocardial Infarction	N/A
Recruiting	`NCT03809689` - Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET	N/A
Completed	`NCT05118009` - Artificial Intelligence Based Rapid Identification of ST-elevation Myocardial Infarction Using Electrocardiogram (ARISE)	N/A
Active, not recruiting	`NCT04753749` - Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy	N/A
Completed	`NCT04769219` - Secondary Prevention Education After Acute Myocardial Infarction	N/A
Active, not recruiting	`NCT05350969` - Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction	Phase 2
Recruiting	`NCT05999110` - Algarve Active Ageing - Cardiac and Osteoarthritis Rehabilitation (A3-COR)	N/A
Completed	`NCT04167904` - Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction
Not yet recruiting	`NCT04989777` - IABP In AMI Patients With SCAI-B Study	N/A
Recruiting	`NCT05043610` - MSCs for Prevention of MI-induced HF	Phase 3
Recruiting	`NCT03600259` - Tianjin Inpatient Acute Myocardial Infarction Registry

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Registry of Acute Myocardial Infarction — RAMI-Tomsk

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms